drugset / Trial / NCT00040170
Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
Phase 2
Terminated
50 enrolled
Transgene
The Cleveland Clinic · collabUniversity of Arizona · collabUniversity of California, Los Angeles · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study involves the use of an experimental product, TG4010. The purpose of the study is to determine if TG4010 can stimulate the body's immune system to help it fight the cancer.
Timeline
- Start
- 2002-05
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MVA-MUC1-IL2 | Vaccine | — | Subcutaneous |